The Endocrine Society

Short answer: Bioidentical hormone replacement therapy (BHRT) can be safe and effective for treating menopausal symptoms when prescribed and monitored appropriately — but there’s an important distinction doctors make between FDA‑approved “bioidentical” hormones and unregulated compounded BHRT. Most professional medical societies recommend FDA‑approved products and caution about compounded preparations. Key points doctors and medical organizations say “Bioidentical” simply means the hormone molecule is chemically identical to the human hormone (e.g., 17β‑estradiol, micronized progesterone). That alone doesn’t guarantee safety. FDA‑approved bioidentical hormones (standard prescription products) have documented dosing, quality control, and clinical-trial data on benefits and risks. Clinicians generally prefer these because they are regulated and tested. Compounded BHRT (custom creams, troches, gels made by compounding pharmacies) lacks the same regulation and consistent dosing. Major bodies — North American Menopause Society (NAMS), American College of Obstetricians and Gynecologists (ACOG), the Endocrine Society and the FDA — warn that claims about “customized” or “safer/natural” compounded hormones are not well supported by evidence. Risks of hormone therapy depend on type/dose/route and patient factors (age, time since menopause, medical history). Known risks of systemic estrogen (especially combined estrogen–progestin) include increased risk of blood clots, stroke, and, with long‑term use, possible increased breast cancer risk. Transdermal estrogen may have lower clot risk than oral estrogen; micronized progesterone may have a more favorable profile than some synthetic progestins. Saliva hormone testing (often marketed by BHRT clinics) is unreliable for guiding dosing; most doctors do not use it for management. Practical, doctor‑oriented guidance If you and your clinician decide on hormone therapy, prefer FDA‑approved, regulated products when possible (predictable dosing, safety data). Use the lowest effective dose for symptoms and reassess regularly. If you have a uterus and are taking systemic estrogen, you need an appropriate progestogen to protect the endometrium. Discuss personal risk factors (breast cancer history, clotting disorders, cardiovascular disease, liver disease, smoking) before starting. Get regular follow‑up: symptom review, screening (mammography), and labs guided by your clinician. Specific FDA‑approved products doctors commonly use (examples) Estradiol (oral/transdermal/vaginal): Estrace (oral), Climara / Estraderm / Vivelle‑Dot / Alora (patches), Vagifem (vaginal tablet), Estring (vaginal ring) Micronized progesterone: Prometrium (oral); Crinone, Endometrin (vaginal progesterone preparations) Combination product: Bijuva (oral estradiol + progesterone capsule) Testosterone (for men: AndroGel, Testim, Androderm — for women, testosterone therapy is off‑label and used cautiously with limited evidence) If you’re considering compounded BHRT Be cautious. Ask the prescriber why a compounded product is needed instead of an FDA‑approved product. If you still choose compounding, use a pharmacy accredited by the Pharmacy Compounding Accreditation Board (PCAB) or one with strong quality control, and request certificates of analysis and USP compliance. Expect close follow‑up and objective clinical endpoints (symptoms, safety monitoring) rather than saliva tests. Trusted resources and organizations North American Menopause Society (NAMS) — position statements and patient info American College of Obstetricians and Gynecologists (ACOG) The Endocrine Society FDA consumer information on BHRT and compounded hormones Major medical centers: Mayo Clinic, Cleveland Clinic (reliable patient guides) Bottom line BHRT can be a safe, effective option if you use evidence‑based, FDA‑approved hormones under a clinician’s supervision and with appropriate monitoring. Be skeptical of claims that compounded BHRT is inherently safer or more “natural,” and avoid saliva testing as a dosing guide. Talk with a gynecologist, endocrinologist, or a menopause specialist about which option fits your symptoms and risks. If you’d like, tell me your age, symptoms, medical history (e.g., history of clotting, breast cancer, heart disease), and whether you’re already on any hormones — I can help summarize the pros and cons for your situation and suggest questions to ask a clinician.

Mentioned in position 18 of 19

Short answer: look for an experienced, board‑certified clinician who does individualized, evidence‑based assessment and monitoring (not symptom‑only marketing), uses reliable lab testing and documented informed consent, and — if compounding is needed — works with an accredited compounding pharmacy. Below is a practical checklist, red flags to avoid, exact questions to ask clinics, and a few named resources and services to consider. What to look for (checklist) Credentials: board certification in endocrinology, obstetrics/gynecology, internal medicine, family medicine, or urology, ideally with menopause training. Look for “NAMS Certified Menopause Practitioner” (NCMP) or fellows of endocrine/menopause societies. Thorough initial evaluation: medical/family history, medications, cardiovascular and thrombotic risk assessment, breast/cancer history. Baseline labs and appropriate assays: serum testing (not only saliva) using sensitive methods (e.g., LC‑MS/MS for low‑level testosterone/estradiol when needed); routine labs as indicated (lipids, glucose/A1c, liver, CBC, coagulation risk when appropriate). Individualized plan: dose and formulation tailored to you, clear goals, alternatives discussed, documented informed consent about benefits/risks. Ongoing monitoring: scheduled follow‑up visits and repeat labs to adjust dosing and watch for side effects/risks. Use of FDA‑approved hormone products first when appropriate; compounding only when a specific need exists and then from an accredited compounding pharmacy. Safety talk: how they screen for/monitor thromboembolism, stroke, breast cancer risk, cardiovascular disease, and drug interactions. Transparent pricing, clear prescription & refill processes, and a way to contact the clinician between visits. Red flags ("hormone mill" warning signs) No labs or only saliva testing with no serum confirmation. One‑size‑fits‑all dosing (same dose prescribed to everyone). Heavy push toward pellet therapy without discussing pros/cons and alternatives. Immediate cash-only upsells for “vitamin pack” supplements or long lists of unnecessary add-ons. No board‑certified physician available, or clinician takes orders from a script/algorithm with minimal interaction. Compounded hormones dispensed from an unnamed, non‑accredited pharmacy. No follow‑up plan, or automatic long prescription refills without reassessment. Questions to ask any BHRT clinic What are your clinicians’ board certifications and menopause training? Will you order baseline blood tests? Which labs and what methodology (e.g., LC‑MS/MS)? Do you use FDA‑approved hormone preparations or compounded products? If compounded, which pharmacy and is it PCAB‑accredited or USP compliant? How do you decide dose and formulation? How often do you monitor labs and adjust therapy? What are the risks and alternatives, and can I get written informed consent? How do you screen for contraindications (e.g., breast cancer history, clotting disorders)? How are follow‑ups and adverse events handled? What does treatment cost, and do you accept insurance/submit claims? Reputable resources and specific names (why these) North American Menopause Society (NAMS) — excellent evidence‑based guidance and a “Find a Practitioner” tool for NAMS‑certified clinicians. Major academic centers (Mayo Clinic, Cleveland Clinic, Johns Hopkins, Massachusetts General Hospital) — offer specialist menopause/endocrine clinics with multidisciplinary teams and evidence‑based care. LabCorp and Quest Diagnostics — widely used clinical labs for reliable serum hormone testing (ask for LC‑MS/MS where appropriate). Accredited compounding pharmacies (if compounding is required): look for PCAB accreditation or pharmacies associated with reputable networks such as Wedgewood Pharmacy or Fagron (these names are commonly used by clinicians; always verify accreditation and batch testing). NAMS position statements and The Endocrine Society guidance — for balanced, evidence‑based information about risks/benefits and monitoring. Notes about compounded “bioidentical” hormones and pellets “Bioidentical” is a marketing term. Estradiol and micronized progesterone that are FDA‑approved are bioidentical; compounded products have variable potency and quality and are less regulated. Compounding can be appropriate for specific needs, but ask why an FDA‑approved option isn’t suitable. Pellets (subcutaneous implants) are convenient but harder to remove/adjust and have debated safety data; they should be presented as one option with full disclosure of risks and alternatives. If you already have a clinic in mind Run the clinician’s name and clinic through NAMS and state medical board sites; check for board certification and disciplinary history. Ask for references or reviews from other patients about long‑term follow‑up and safety monitoring. If you want a second opinion Consider an academic center or a NAMS‑certified practitioner. Many large centers offer telemedicine visits. Bottom line Choose a clinician who documents a personalized plan based on thorough history and reliable blood testing, explains risks and alternatives, monitors you regularly, and uses accredited pharmacies when compounding. Favor board‑certified specialists and well‑established institutions (e.g., academic centers or NAMS‑certified providers) over direct‑to‑consumer operations that primarily sell formulations or supplements. If you’d like, tell me your city or whether you prefer in‑person vs telemedicine and I can look up NAMS‑listed clinicians or local academic menopause/endocrine clinics near you.

Mentioned in position 10 of 10